

Vuzix Corp  
Form 10-Q  
May 12, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE  
ACT OF 1934**

**For the Quarterly Period Ended March 31, 2015**

**OR**

**..TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT  
OF 1934**

**Commission file number 001-35955**

**VUZIX CORPORATION**

**(Exact name of registrant as specified in its charter)**

|                                       |                            |
|---------------------------------------|----------------------------|
| <b>Delaware</b>                       | <b>04-3392453</b>          |
| <b>State or other jurisdiction of</b> | <b>(I.R.S. Employer</b>    |
| <b>incorporation or organization</b>  | <b>Identification No.)</b> |

**2166 Brighton Henrietta Townline Rd**  
**14623**  
**Rochester, New York**  
**(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code: (585) 359-5900**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company   
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act). Yes  No

As of May 12, 2015, there were 15,909,978 shares of the registrant's common stock outstanding.

**Vuzix Corporation**

**INDEX**

|  | <b>Page No.</b> |
|--|-----------------|
| Part I – Financial Information   |                 |
| Item 1. Condensed Consolidated Financial Statements (Unaudited):   |                 |
| <u>Consolidated Balance Sheets as of March 31, 2015 and December 31, 2014</u>  | 3               |
| <u>Consolidated Statement of Changes in Stockholder’s Equity (Deficit) for the Three Months Ended March 31, 2015</u> | 4               |
| <u>Consolidated Statements of Operations for the Three Months Ended March 31, 2015 and 2014</u>                      | 5               |
| <u>Consolidated Statement of Cash Flows for the Three Months Ended March 31, 2015 and 2014</u>                       | 6               |
| <u>Notes to the Unaudited Condensed Consolidated Financial Statements</u>  | 7               |
| Item 2. <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>                 | 15              |
| Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>  | 22              |
| Item 4. <u>Controls and Procedures</u>   | 22              |
| Part II – Other Information  |                 |
| Item 1. <u>Legal Proceedings</u>   | 23              |
| Item 1A. <u>Risk Factors</u>   | 23              |
| Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>   | 23              |
| Item 3. <u>Defaults Upon Senior Securities</u>   | 24              |
| Item 4. <u>Mine Safety Disclosure</u>  | 24              |
| Item 5. <u>Other Information</u>   | 24              |
| Item 6. <u>Exhibits</u>  | 24              |
| <u>Signatures</u>  | 25              |



**Part 1: FINANCIAL INFORMATION****Item 1: Condensed Consolidated Financial Statements (Unaudited)****VUZIX CORPORATION****CONSOLIDATED BALANCE SHEETS****(Unaudited)**

|   | March 31,<br>2015 | December 31,<br>2014 |
|---|-------------------|----------------------|
| <b>ASSETS</b>   |                   |                      |
| Current Assets  |                   |                      |
| Cash and Cash Equivalents                             | \$22,884,309      | \$84,967             |
| Accounts Receivable                                   | 255,126           | 383,533              |
| Inventories, Net (Note 3)                             | 1,013,467         | 911,949              |
| Prepaid Expenses and Other Assets                     | 383,136           | 579,000              |
| Total Current Assets                                  | 24,536,038        | 1,959,449            |
| Tooling and Equipment, Net                            | 387,263           | 416,965              |
| Patents and Trademarks, Net                           | 419,771           | 423,489              |
| Software Development Costs, Net                       | 716,126           | 787,738              |
| Debt Issuance Costs, Net                              | 101,068           | 112,521              |
| Total Assets  | \$26,160,266      | \$3,700,162          |
| <b>LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</b> |                   |                      |
| Current Liabilities                                   |                   |                      |
| Accounts Payable                                      | \$827,988         | \$2,183,565          |
| Line of Credit  | —                 | 112,500              |
| Note Payable (Note 4)                                 | —                 | 37,038               |
| Current Portion of Long-Term Debt (Note 7)            | 80,097            | 128,425              |
| Current Portion of Capital Leases                     | 11,629            | 16,882               |
| Customer Deposits                                     | 19,057            | 120,550              |
| Unearned Revenue                                      | 68,489            | 53,403               |
| Accrued Expenses (Note 5)                             | 673,737           | 699,067              |
| Income and Other Taxes Payable                        | 29,098            | 35,158               |
| Total Current Liabilities                             | 1,710,095         | 3,386,588            |

Edgar Filing: Vuzix Corp - Form 10-Q

|   |              |              |
|---|--------------|--------------|
| Long-Term Liabilities   |              |              |
| Long-Term Derivative Liability (Note 6)   | 175,158      | 13,541,138   |
| Long-Term Portion of Term Debt, net of discount (Note 7)  | 1,077,009    | 1,088,996    |
| Long-Term Portion of Accrued Interest   | 103,921      | 81,451       |
| Total Long-Term Liabilities   | 1,356,088    | 14,711,585   |
| Total Liabilities   | 3,066,183    | 18,098,173   |
| Stockholders' Equity (Deficit)  |              |              |
| Preferred Stock — \$.001 Par Value, 5,000,000 Shares Authorized; 49,626 Shares Issued and Outstanding March 31, 2015, and 0 Shares Outstanding on December 31, 2014 | 50           | —            |
| Common Stock — \$.001 Par Value, 100,000,000 Shares Authorized; 15,865,141 Shares Issued and Outstanding March 31, 2015 and 11,295,387 on December 31, 2014         | 15,865       | 11,296       |
| Additional Paid-in Capital  | 72,330,410   | 29,752,083   |
| Accumulated Deficit   | (49,252,242) | (44,161,390) |
| Total Stockholders' Equity (Deficit)  | 23,094,083   | (14,398,011) |
| Total Liabilities and Stockholders' Equity (Deficit)  | \$26,160,266 | \$3,700,162  |

The accompanying notes are an integral part of these consolidated financial statements.

## VUZIX CORPORATION

## CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)

(Unaudited)

|   | Common Stock |           | Additional<br>Paid-In<br>Capital | Accumulated<br>Deficit | Preferred<br>Stock |        | Total          |
|---|--------------|-----------|----------------------------------|------------------------|--------------------|--------|----------------|
|   | Shares       | Amount    |                                  |                        | Shares             | Amount |                |
| <b>Balance — December 31, 2014</b>  | 11,295,387   | \$ 11,296 | \$ 29,752,083                    | \$(44,161,390)         | —                  | \$ —   | \$(14,398,011) |
| Stock Compensation Expense  |              |           | 113,084                          |                        |                    |        | 113,084        |
| Conversion of Note Payable  | 150,000      | 150       | 337,350                          |                        |                    |        | 337,500        |
| Stock Issues for Services   | 40,000       | 40        | 235,460                          |                        |                    |        | 235,500        |
| Common Stock Awards to<br>Officers, Directors and Law<br>Firm   | 295,000      | 295       | 1,474,705                        |                        |                    |        | 1,475,000      |
| Warrants Issued for Services  |              |           | 260,373                          |                        |                    |        | 260,373        |
| Exercise of Warrants  | 4,084,754    | 4,084     | 1,196,667                        |                        |                    |        | 1,200,751      |
| Reclass Fair Value of Warrant<br>Derivative Liability upon<br>Exercise                                      |              |           | 2,826,053                        |                        |                    |        | 2,826,053      |
| Reclass Fair Value of Warrant<br>Derivative Liability Upon<br>Waiver of Certain<br>Anti-Dilutive Provisions |              |           | 8,736,412                        |                        |                    |        | 8,736,412      |
| Reclass Fair Value of Note<br>Derivative Liability Upon<br>Waiver of Certain<br>Anti-Dilutive Provisions    |              |           | 2,806,942                        |                        |                    |        | 2,806,942      |
| Proceeds from Preferred Stock<br>Offering   |              |           | 24,812,950                       |                        | 49,626             | 50     | 24,813,000     |
| Direct costs of preferred stock<br>Offering   |              |           | (221,669 )                       |                        |                    |        | (221,669 )     |
| Net Loss for the Quarter<br>Ended March 31, 2015  |              |           |                                  | (5,090,852 )           |                    |        | (5,090,852 )   |
| <b>Balance — March 31, 2015</b>   | 15,865,141   | \$ 15,865 | \$ 72,330,410                    | \$(49,252,242)         | 49,626             | \$ 50  | \$ 23,094,083  |

The accompanying notes are an integral part of these consolidated financial statements.





**VUZIX CORPORATION****CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS****(Unaudited)**

|  | For Three Months Ended<br>March 31, |                    |
|--|-------------------------------------|--------------------|
|  | 2015                                | 2014               |
| Sales of Products                                      | \$695,574                           | \$649,418          |
| Sales of Engineering Services                          | 113,581                             | 149,000            |
| <b>Total Sales</b>                                     | <b>809,155</b>                      | <b>798,418</b>     |
| Cost of Sales — Products                               | 585,390                             | 390,649            |
| Cost of Sales — Engineering Services                   | 45,432                              | 59,600             |
| <b>Total Cost of Sales</b>                             | <b>630,822</b>                      | <b>450,249</b>     |
| <b>Gross Profit</b>                                    | <b>178,333</b>                      | <b>348,169</b>     |
| Operating Expenses:                                    |                                     |                    |
| Research and Development                               | 514,707                             | 397,422            |
| Selling and Marketing                                  | 357,547                             | 364,555            |
| General and Administrative                             | 2,934,907                           | 479,637            |
| Depreciation and Amortization                          | 59,638                              | 99,705             |
| <b>Total Operating Expenses</b>                        | <b>3,866,799</b>                    | <b>1,341,319</b>   |
| <b>(Loss) from Operations</b>                          | <b>(3,688,466 )</b>                 | <b>(993,150 )</b>  |
| Other Income (Expense)                                 |                                     |                    |
| Other Taxes  | (11,774 )                           | (21,442 )          |
| Foreign Exchange Gain (Loss)                           | 5,271                               | (3,951 )           |
| Gain (Loss) on Derivative Valuation                    | (1,003,427 )                        | 2,575,262          |
| Amortization of Term Debt Discount                     | (340,960 )                          | (6,326 )           |
| Interest Expense                                       | (51,496 )                           | (38,487 )          |
| <b>Total Other Income (Expense)</b>                    | <b>(1,402,386 )</b>                 | <b>2,505,056</b>   |
| <b>Income (Loss) Before Provision for Income Taxes</b> | <b>(5,090,852 )</b>                 | <b>1,511,906</b>   |
| <b>Provision (Benefit) for Income Taxes</b>            | <b>—</b>                            | <b>—</b>           |
| <b>Net Income (Loss)</b>                               | <b>\$(5,090,852 )</b>               | <b>\$1,511,906</b> |
| <b>Preferred Stock Dividends</b>                       | <b>(358,939 )</b>                   | <b>—</b>           |
| <b>Earnings Available to Common Shareholders</b>       | <b>(5,449,791 )</b>                 | <b>1,511,906</b>   |

Edgar Filing: Vuzix Corp - Form 10-Q

Earnings (Loss) per Share (Note 2)

|                                      |            |   |            |
|--------------------------------------|------------|---|------------|
| Basic                                | \$(0.40    | ) | \$0.15     |
| Diluted                              | \$(0.40    | ) | \$0.13     |
| Weighted-average Shares Outstanding: |            |   |            |
| Basic                                | 13,561,206 |   | 9,972,105  |
| Diluted                              | 13,561,206 |   | 11,517,104 |

The accompanying notes are an integral part of these condensed consolidated financial statements.

**VUZIX CORPORATION****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS****(Unaudited)**

|  | For the Three Months<br>Ended<br>March 31, |             |
|--|--|-------------|
|  | 2015                                       | 2014        |
| Cash Flows from Operating Activities                                 |  |             |
| Net Income (Loss)  | \$(5,090,852 )                             | \$1,511,906 |
| Non-Cash Adjustments   |  |             |
| Depreciation and Amortization  | 59,639                                     | 99,705      |
| Amortization of Software Development Costs in cost of sales products | 71,613                                     | —           |
| Common Stock Awards Compensation Expense                             | 1,475,000                                  | —           |
| Stock-Based Option Compensation Expense                              | 113,084                                    | 19,347      |
| Amortization of Term Debt Discount                                   | 340,960                                    | 6,326       |
| Amortization of Debt Issuance Costs                                  | 11,453                                     | —           |
| Common Stock and Warrants Issued for Services                        | 526,916                                    | —           |
| (Gain) Loss on Derivative Valuation                                  | 1,003,427                                  | (2,575,262) |
| (Increase) Decrease in Operating Assets                              |  |             |
| Accounts Receivable  | 128,407                                    | 27,130      |
| Inventories  | (101,518 )                                 | (82,047 )   |
| Prepaid Expenses and Other Assets                                    | 164,821                                    | 136,026     |
| Increase (Decrease) in Operating Liabilities                         |  |             |
| Accounts Payable   | (1,355,578 )                               | (146,719 )  |
| Accrued Expense  | (25,330 )                                  | (13,700 )   |
| Customer Deposits  | (101,493 )                                 | (72,409 )   |
| Unearned Revenue   | 15,086                                     | —           |
| Income and Other Taxes Payable                                       | (6,060 )                                   | 10,678      |
| Accrued Interest   | 22,470                                     | 5,708       |
| Net Cash Flows Used in From Operating Activities                     | (2,747,955 )                               | (1,073,311) |
| Cash Flows from Investing Activities                                 |  |             |
| Purchases of Tooling and Equipment                                   | (18,310 )                                  | (57,009 )   |
| Investments in Software  | —  | (280,585 )  |
| Investments in Patents and Trademarks                                | (7,909 )                                   | (11,305 )   |
| Net Cash Used in Investing Activities                                | (26,219 )                                  | (348,899 )  |
| Cash Flows from Financing Activities                                 |  |             |
| Proceeds from Exercise of Warrants                                   | 1,200,751                                  | 1,447,425   |

Edgar Filing: Vuzix Corp - Form 10-Q

|  |                  |               |
|--|------------------|---------------|
| Repayment of Capital Leases  | (5,253 )         | (8,042 )      |
| Repayment of Long-Term Debt and Notes Payable  | (100,813 )       | (55,501 )     |
| Proceeds from Preferred Stock Offering   | 24,813,000       | —             |
| Issuance Costs on Preferred Stock Offering   | (221,669 )       | —             |
| Net Change in Lines of Credit  | (112,500 )       | —             |
| <br>Net Cash Flows Provided by Financing Activities  | <br>25,573,516   | <br>1,383,882 |
| <br>Net Increase (Decrease) in Cash and Cash Equivalents   | <br>22,799,342   | <br>(38,328 ) |
| Cash and Cash Equivalents — Beginning of Period  | 84,967           | 310,140       |
| <br>Cash and Cash Equivalents — End of Period  | <br>\$22,884,309 | <br>\$271,812 |
| Supplemental Disclosures   |                  |               |
| Interest Paid  | \$17,794         | \$32,779      |
| Common Stock and Warrants Issued for Services, Classified as Prepaid Expense   | 138,625          | —             |
| Conversion of Long-Term Debt   | 337,500          | —             |
| Reclassification of Derivative Liability to Paid-In Capital upon Waiver of Certain Anti-Dilutive Provisions of Warrants and Convertible Debt | 11,543,354       | —             |
| Reclassification of Derivative Liability Upon Warrant Exercises  | 2,826,053        | —             |

The accompanying notes are an integral part of these condensed consolidated financial statements.

## **VUZIX CORPORATION AND SUBSIDIARIES**

### **NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

#### **Note 1 — Basis of Presentation**

The accompanying unaudited Condensed Consolidated Financial Statements of Vuzix Corporation and Subsidiaries ("the Company") have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission. Accordingly, the unaudited Condensed Consolidated Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. The condensed consolidated balance sheet as of December 31, 2014 was derived from the audited Consolidated Financial Statements in Form 10-K.

The accompanying Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements of the Company as of December 31, 2014, as reported in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission.

The results of the Company's operations for any interim period are not necessarily indicative of the results of the Company's operations for any other interim period or for a full fiscal year.

#### **Note 2 – Earnings (Loss) Per Share**

Basic earnings (loss) per share is computed by dividing net income or loss by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution from the assumed exercise of stock options and warrants, and the conversion of any convertible debt and convertible preferred shares. During periods of net loss, all common stock equivalents are excluded from the diluted EPS calculation because they are antidilutive. Since the Company reported a net loss for the three months ended March 31, 2015, the calculation for basic and diluted earnings per share is considered to be the same, as the impact of potential common shares is anti-dilutive. Since the Company reported net income for the three months ended March 31, 2014, a total of 1,544,999 additional shares have been included for these diluted calculations. As of March 31, 2015 and December 31, 2014, there were 7,186,350 and 7,012,767 respectively, common stock share equivalents potentially issuable under convertible debt agreements, conversion of preferred shares, options, and warrants that could potentially dilute basic

earnings per share in the future.

**Note 3 — Inventories, Net**

Inventories are stated at the lower of cost (determined on the first-in, first-out or specific identification method) or market and consisted of the following as at March 31, 2015 and December 31, 2014:

|                                | March 31,<br>2015 | December<br>31, 2014 |
|--------------------------------|-------------------|----------------------|
| Purchased Parts and Components | \$923,363         | \$1,251,224          |
| Work in Process                | 14,702            | 25,974               |
| Finished Goods                 | 405,577           | 300,889              |
| Less: Reserve for Obsolescence | (330,175 )        | (666,138 )           |
| Net                            | \$1,013,467       | \$911,949            |

**Note 4 — Notes Payable**

Notes payable represent promissory notes payable by the Company.

|  | March<br>31,<br>2015 | December<br>31, 2014 |
|--|----------------------|----------------------|
| Note payable to officers and shareholders of the Company. Principal along with accrued interest is payable on demand. The notes bear interest at 18.5% and secured by all the assets of the Company. | \$—                  | \$ 37,038            |
|  | \$—                  | \$ 37,038            |

### Note 5 — Accrued Expenses

Accrued expenses consisted of the following:

|                                 | March<br>31, 2015 | December<br>31, 2014 |
|---------------------------------|-------------------|----------------------|
| Accrued Wages and Related Costs | \$91,134          | \$ 101,445           |
| Accrued Compensation            | 417,286           | 428,786              |
| Accrued Professional Services   | 33,500            | 45,000               |
| Accrued Warranty Obligations    | 45,623            | 39,624               |
| Accrued Interest                | 85,191            | 75,471               |
| Other Accrued Expenses          | 1,003             | 8,741                |
| Total                           | \$673,737         | \$699,067            |

Included in the above accrued compensation are amounts owed to officers of the Company for services rendered that remain outstanding. These amounts are not subject to a fixed repayment schedule and they bear interest at a rate of 8% per annum, compounding monthly. The amounts were \$386,036 as of March 31, 2015 and \$393,526 as of December 31, 2014. The related interest amounts included in Accrued Interest were \$71,076 and \$62,801 respectively as of March 31, 2015 and December 31, 2014. The related interest expense amounts for the three months ended March 31, 2015 and 2014 were \$8,994 and \$7,338 respectively.

The Company has warranty obligations in connection with the sale of certain of its products. The warranty period for its products is generally one year except in certain European countries where it is two years. The costs incurred to provide for these warranty obligations are estimated and recorded as an accrued liability at the time of sale. The Company estimates its future warranty costs based on product-based historical performance rates and related costs to repair. The changes in the Company's accrued warranty obligations for the three months ended March 31, 2015 were as follows:

|   |          |
|---|----------|
| Accrued Warranty Obligations at December 31, 2014 | \$39,624 |
| Reductions for Settling Warranties                | (21,948) |
| Warranties Issued During Period                   | 27,947   |
| Accrued Warranty Obligations at March 31, 2015    | \$45,623 |

**Note 6 – Derivative Liability and Fair Value Measurements**

The Company recognized a derivative liability for the warrants to purchase shares of its common stock issued in connection with the public equity offering and related debt conversions on August 5, 2013. These warrants have a cashless exercise provision and an exercise price that is subject to adjustment in the event of subsequent equity sales at a lower purchase price (subject to certain exceptions) along with full-ratchet anti-dilution provisions. In accordance with ASC 815-10-25, we measured the derivative liability using a Monte Carlo Options Lattice pricing model at their issuance date and subsequently remeasured the liability on each reporting date.

Accordingly, at the end of each quarterly reporting date the derivative fair market value is remeasured and adjusted to current market value. As at March 31, 2015 a total of 52,600 of these warrants were outstanding and as at December 31, 2014 a total of 4,730,992 warrants were outstanding that contained a full-ratchet anti-dilution provision. In connection with the Series A Private Placement on January 2, 2015 (see Note 9), holders of approximately 86% of outstanding warrants issued by the Company in its public offering and in connection with the conversion by certain holders of the Company’s outstanding debt in connection with the Company’s public offering (collectively, the “Public Offering Warrants”) agreed to irrevocably waive their rights to anti-dilution protection under Section 2(b) of the Public Offering Warrants in the event the Company issues additional securities at a per share price lower than the exercise price of the Public Offering Warrants (the “Public Offering Warrant Waiver”). As a result the related derivative liability was reversed to Nil and reclassified into stockholders equity under Additional Paid-In Capital.



The Company recognized a derivative liability during the year ended December 31, 2014 for the \$3,000,000 of senior convertible notes with a conversion price that is subject to adjustment in the event of subsequent equity sales at a lower purchase price (subject to certain exceptions). In accordance with FASB ASC 815-10-25, we measured the derivative liability of this embedded conversion option using a Monte Carlo Options Lattice pricing model at the June 3, 2014 issuance date as \$1,938,988. The value of the derivative liability at issuance was recorded as a discount against the notes in the Long-Term Liabilities section of the balance sheet which is amortized into interest expense over the term of the related note. At the end of each quarterly reporting date the derivative fair market value is remeasured and adjusted to current market value through earnings.

In connection with the Series A Private Placement on January 2, 2015, each of the holders of notes issued by the Company on June 3, 2014 (the "June 2014 Notes") agreed to irrevocably waive their rights to anti-dilution protection under Section 5(b) of the June 2014 Notes in the event the Company issues additional securities at a per share price lower than the conversion price of the June 2014 Notes (the "June 2014 Note Waiver"). As a result this derivative liability was reversed to Nil and reclassified into stockholders equity under Additional Paid-In Capital. For period ending December 31, 2014, the Monte Carlo Options Lattice pricing model was used to estimate the fair value of the embedded conversion option on the convertible notes issued during this period.

The Company has adopted FASB ASC Topic 820 for financial instruments measured at fair value on a recurring basis. ASC Topic 820 defines fair value, establishes a framework for measuring fair value in accordance with accounting principles generally accepted in the United States and expands disclosures about fair value measurements.

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC Topic 820 establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:

- Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;
- Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
- Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

Edgar Filing: Vuzix Corp - Form 10-Q

The Company's financial instruments primarily consists of cash and cash equivalents, accounts receivable, accounts payable, lines of credit, long-term debt and capital leases, customer deposits, accrued expenses, and income taxes payable.

As of the consolidated balance sheet dates, the estimated fair values of the financial instruments were not materially different from their carrying values as presented due to both the short maturities of these instruments and that the interest rates on borrowing approximate those that would have been available for loans for similar remaining maturity and risk profiles.

We measure certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows at March 31, 2015:

|  | Total     | (Level<br>1) | (Level<br>2) | Level (3) |
|--|-----------|--------------|--------------|-----------|
| Assets   | \$—       | \$ —         | \$ —         | \$—       |
| Total assets measured at fair value                  | —         | —            | —            | —         |
| Liabilities  |           |              |              |           |
| Note Conversion Feature Liability                    | —         | —            | —            | —         |
| Warrant Liability                                    | 175,158   | —            | —            | 175,158   |
| Total liabilities measured at fair value (Long-Term) | \$175,158 | \$ —         | \$ —         | \$175,158 |

We measure certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows at December 31, 2014:

|  | Total         | (Level<br>1) | (Level<br>2) | Level (3)     |
|--|---------------|--------------|--------------|---------------|
| Assets   | \$—           | \$ —         | \$ —         | \$—           |
| Total assets measured at fair value                  | —             | —            | —            | —             |
| <b>Liabilities</b>                                   |               |              |              |               |
| Note Conversion Feature Liability                    | 2,806,942     | —            | —            | 2,806,942     |
| Warrant Liability                                    | 10,734,196    | —            | —            | 10,734,196    |
| Total liabilities measured at fair value (Long-Term) | \$ 13,541,138 | \$ —         | \$ —         | \$ 13,541,138 |

|   |              |
|---|--------------|
| Fair value – December 31, 2014  | 13,541,138   |
| Reclassification of warrant exercises to Additional Paid-in Capital   | (2,826,053 ) |
| Change in fair value for the period of warrant derivative liability   | 1,003,427    |
| Reclassification of embedded debt conversion price adjustment provision liability to Additional Paid-in Capital upon waiver of certain anti-dilutive provisions | (2,806,942 ) |
| Reclassification of warrant exercise price adjustment provision liability to Additional Paid-in Capital upon waiver of certain anti-dilutive provisions         | (8,736,412 ) |
| Fair value – March 31, 2015   | \$ 175,158   |

The Monte Carlo Options Lattice pricing model was used to estimate the fair value of the warrant liability outstanding:

|                                       | March 31, 2015 | December 31,<br>2014 |
|---------------------------------------|----------------|----------------------|
| <b>Assumptions for Pricing Model:</b> |                |                      |
| Expected term in years                | 3.35 to 3.59   | 3.59 to 3.78         |
| Volatility range for years            | 89 to 90%      | 81 to 89%            |
| Risk-free interest rate               | 0.89 to 1.06%  | 0.83 to 1.11%        |
| Expected annual dividends             | None           | None                 |
| <b>Value of warrants outstanding:</b> |                |                      |
| Fair value of warrants                | \$ 175,158     | \$ 10,734,196        |



**Note 7 — Long-Term Debt**

Long-term debt consisted of the following:

|  | March 31,<br>2015 | December 31,<br>2014 |
|--|-------------------|----------------------|
| Note payable for research and development equipment. The principal is subject to a fixed semi-annual repayment schedule commencing October 31, 2013 over 48 months. The note carries a 0% interest rate.   | 130,836           | 186,131              |
| The note carries a 0% interest, but imputed interest has been accrued based on a 12% discount rate and is reflected as a reduction in the principal.   | (40,074 )         | (46,399 )            |
| Note payable for which the principal and interest is subject to a fixed blended repayment schedule of 36 months, commencing July 15, 2013. The loan bears interest at 12% per annum and is secured by a subordinated position in all the assets of the Company.  | 42,395            | 50,874               |
| Convertible, Senior Secured Notes payable. The principal is due June 3, 2017 and no principal payments are required. The notes carry a 5% interest, payable upon the note's maturity. Both the interest plus accrued interest is convertible into shares of the Company's common shares at \$2.25, subject to normal adjustments. The notes are secured by a first security position in all the assets of the Company. | 2,037,500         | 2,375,000            |
| Unamortized debt discount related to derivative liability associated with above notes' conversion price that is subject to adjustment in the event of subsequent equity sales at a lower purchase price (subject to certain exceptions). Upon issuance on June 3, 2014 the discount was \$1,938,988.   | (1,013,551)       | (1,348,185 )         |
|  | \$1,157,106       | \$ 1,217,421         |
| Less: Amount Due Within One Year   | (80,097 )         | (128,425 )           |
| Amount Due After One Year  | \$1,077,009       | \$ 1,088,996         |

The calendar year aggregate maturities for all long-term borrowings exclusive of discounts as of March 31, 2015 are as follows:

| <u>Total Aggregate Maturity For Period</u>                    | Amounts    |
|---|------------|
| 2015  | \$ 114,088 |
| 2016  | 59,143     |
| 2017  | 2,037,500  |
| Total Required Principal Payments Exclusive of Debt Discounts | 2,210,731  |

Edgar Filing: Vuzix Corp - Form 10-Q

|   |             |
|---|-------------|
| Total Unamortized Debt Discounts                    | (1,053,625) |
| Total Net Long-Term Borrowings as of March 31, 2015 | \$1,157,106 |

## Note 8 — Income Taxes

The Company's effective income tax rate is a combination of federal, state and foreign tax rates and differs from the U.S. statutory rate due to taxes on foreign income, permanent differences including tax-exempt interest, and the resolution of tax uncertainties, offset by a valuation allowance against U.S. deferred income tax assets.

## Note 9 — Preferred Stock

The Company may issue shares of undesignated preferred stock in one or more series. The Board of Directors is authorized to establish and designate the different series and to fix and determine the voting powers and other special rights and qualifications. A total of 5,000,000 shares of preferred stock are authorized as of March 31, 2015 and December 31, 2014.

On January 2, 2015 (the "Series A Closing Date"), we entered into and closed a Series A Preferred Stock Purchase Agreement (the "Series A Purchase Agreement") with Intel Corporation (the "Series A Purchaser"), pursuant to which we issued and sold to the Series A Purchaser, an aggregate of 49,626 shares of the Company's Series A Preferred Stock, at a purchase price of \$500 per share, for an aggregate purchase price of \$24,813,000 (the "Series A Private Placement"). Each share of Series A Preferred Stock is convertible, at the option of the Series A Purchaser, into 100 shares of the Company's common stock (determined by dividing the Series A Original Issue Price of \$500 by the Series A Conversion Price. The Series A Conversion Price is \$5.00, subject to adjustment in the event of stock splits, dividends or other combinations). Total costs incurred connection with this offering were approximately \$222,000.

Each share of Series A Preferred Stock is entitled to receive dividends at a rate of 6% per annum, compounded quarterly and payable in cash or in kind, at the Company's sole discretion. In the event of the liquidation, dissolution or winding up of the Company, each share of Series A Preferred Stock is entitled to a liquidation preference equal to one times (1x) the Series A Purchaser's original per share purchase price, plus a right to receive an additional liquidation distribution together with the common stock holders pro rata on an as converted basis, but not in excess of \$1,000 per share in the aggregate (subject to adjustment for accrued but unpaid dividends and in the event of stock splits, dividends or other combinations). Each share of Series A Preferred Stock is entitled to vote with the holders of the Company's common stock on matters presented to its stockholders, and is entitled to cast such number of votes equal to the whole number of shares of common stock into which such shares of Series A Preferred Stock are convertible. The holders of record of the Series A Preferred Stock will be entitled to nominate and elect 2 directors to the Company's Board of Directors (the "Board Election Right"), at least one of whom will be required to qualify as an "independent" director, as that term is used in applicable exchange listing rules. The Board Election Right with respect to the independent director will terminate on such date as the number of shares of Series A Preferred Stock then outstanding is less than 40% of the original amount purchased by the Series A Purchaser. The Board Election Right with respect to the second director shall terminate on such date as the number of shares of Series A Preferred Stock

then outstanding is less than 20% of the original amount purchased by the Series A Purchaser. The Company also granted the Series A Purchaser the right to have a board observer at meetings of the Company's Board of Directors and committees thereof.

For as long as at least 25% (or 12,406 shares) of the Series A Preferred Stock is outstanding, the Company may not, without the consent of holders of at least 60% of the then outstanding shares of Series A Preferred Stock, take certain actions, including but not limited to: (i) liquidate, dissolve, or wind up the business and affairs of the Company; (ii) amend, alter or repeal any provision of its charter or bylaws in a manner that adversely effects the rights of the Series A Preferred Stock; (iii) create or issue any capital stock that is equal to or senior to the Series A Preferred Stock with respect to preferences; (iv) create or issue any debt security, subject to certain exceptions; (v) pay off any debt obligation prior to its stated maturity date; or (vi) enter into any stockholders rights plan or similar arrangement or take other actions that may limit actions that holders of a majority of the Series A Preferred Stock can take under Section 203 ("Section 203") of the Delaware General Corporation Law, as well as such other customary provisions protecting the rights of the holder of the Series A Preferred Stock, as are outlined in the Certificate of Designation.

The Series A Purchaser has the right to participate in any proposed issuance by the Company of its securities, subject to certain exceptions (the "Participation Right"). In the event the Series A Purchaser is not afforded the opportunity to exercise its Participation Right, the Series A Purchaser will have the right, but not the obligation, up to two times per calendar year, to acquire additional securities from the Company in such amount as is sufficient to maintain the Series A Purchaser's ownership percentage in the Company, calculated immediately prior to such applicable financing, at a purchase price equal to the per share price of the Company's securities in such applicable financing.

In connection with the Series A Private Placement, the Company entered into an investor's rights agreement with the Series A Purchaser, pursuant to which the Company agreed to file a "resale" registration statement with the Securities and Exchange Commission (the "SEC") covering all shares of common stock issuable upon conversion of the Series A Preferred Stock sold in the Series A Private Placement on or before February 14, 2015. The Company filed the registration statement on February 12, 2015 and the registration statement was declared effective by SEC on February 17, 2015.



**Note 10 — Stock Warrants**

A summary of the various changes in warrants during the three-month period ended March 31, 2015 is as follows.

|   | Number of<br>Shares |
|---|---------------------|
| Warrants Outstanding at December 31, 2014 | 5,236,660           |
| Exercised During the Period               | (4,699,017)         |
| Issued During the Period                  | 60,000              |
| Expired During the Period                 | —                   |
| Warrants Outstanding, March 31, 2015      | 597,643             |

The outstanding warrants as of March 31, 2015 expire from May 21, 2015 to August 5, 2018. The weighted average remaining term of the warrants is 2.9 years. The weighted average exercise price is \$2.56 per share.

The Black-Scholes-Merton pricing model was used to estimate the fair value of share-based awards under FASB ASC Topic 718. The Black-Scholes-Merton pricing model incorporates various and highly subjective assumptions, including expected term and expected volatility.

The following shows the assumptions used to compute the fair value of warrants granted during the three period ending March 31, 2015 for investor relations services and their estimated value:

- Expected term in years J.8 to 3.0 years
- Volatility I22.8 to 122.9%
- Risk-free interest rate H.90 to 0.99%
- Expected annual dividends None
- Fair value of warrants issued \$260,373

Unrecognized warrant-based compensation expense was approximately \$61,082 as of March 31, 2015, relating to the unamortized period of services remaining under the arrangements for which the warrants were issued. The entire unamortized amount will be recognized in the second quarter ending June 30, 2015.

**Note 11 — Stock Option Plans**

A summary of stock option activity for the three months ended March 31, 2015 is as follows:

|                                  | Number<br>of<br>Shares | Weighted<br>Average<br>Exercise<br>Price | Exercise Price<br>Range |
|----------------------------------|------------------------|--|-------------------------|
| Outstanding at December 31, 2014 | 720,551                | \$ 4.46                                  | \$ 1.71 – \$ 17.50      |
| Granted                          | —                      | \$ —                                     | \$—                     |
| Exercised                        | —                      | \$ —                                     | \$—                     |
| Expired or Forfeited             | —                      | \$ —                                     | \$—                     |
| Outstanding at March 31, 2015    | 720,551                | \$ 4.46                                  | \$ 1.71 – \$ 17.50      |

As of March 31, 2015, there were 304,337 options that were fully vested and exercisable at a weighted average exercise price of \$6.95 per share. The weighted average remaining contractual term on the vested options is 6.9 years.

As of March 31, 2015 there were 416,214 unvested options exercisable at a weighted average exercise price of \$2.63 per share. The weighted average remaining contractual term on the unvested options is 9.3 years.

No cash was received from option exercises for the three months ended March 31, 2015 and 2014.

The weighted average fair value of option grants was calculated using the Black-Scholes-Merton option pricing method. At March 31, 2015, the Company had approximately \$957,291 of unrecognized stock compensation expense, which will be recognized over a weighted average period of approximately 2.0 years.

#### **Note 12 — Litigation**

We are not currently involved in any pending legal proceeding or litigation.

#### **Note 13 — Contractual Obligations**

The Company leases office and manufacturing space under operating leases that expire on September 30, 2015 through to March 1, 2016. The Company's total contractual payment obligations for operating leases as of March 31, 2015 total \$66,800.

#### **Note 14 — Recent Accounting Pronouncements**

FASB ASU 2015-1, Income Statement—Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items This ASU eliminates from GAAP the concept of extraordinary items. ASU 2015-1 is effective for the annual period ending after December 15, 2015. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption.

FASB ASU 2015-03—Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. This ASU requires that debt issuance costs be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability (same treatment as debt discounts). ASU 2015-3 is effective for the annual periods beginning after December 15, 2015. Early adoption is permitted for financial statements that not have been previously issued.

There are no other recent accounting pronouncements that are expected to have a material impact on the condensed consolidated financial statements.



## **Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*You should read the following discussion and analysis of financial condition and results of operations in conjunction with the financial statements and related notes appearing elsewhere in this quarterly report and in our annual report on Form 10-K for the year ended December 31, 2014*

*As used in this report, unless otherwise indicated, the terms "Company," "Vuzix" "management," "we," "our," and "us" refer to Vuzix Corporation and its subsidiary.*

### ***Critical Accounting Policies and Significant Developments and Estimates***

The discussion and analysis of our financial condition and results of operations are based on our unaudited condensed consolidated financial statements and related notes appearing elsewhere in this quarterly report. The preparation of these statements in conformity with generally accepted accounting principles requires the appropriate application of certain accounting policies, many of which require us to make estimates and assumptions about future events and their impact on amounts reported in our financial statements, including the statement of operations, balance sheet, cash flow and related notes. We continually evaluate our estimates used in the preparation of our financial statements, including those related to revenue recognition, bad debts, inventories, warranty reserves, product warranty, carrying value of long-lived assets, fair value measurement of financial instruments and embedded derivatives, valuation of stock compensation awards, and income taxes. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not apparent from other sources. Since future events and their impact cannot be determined with certainty, the actual results will inevitably differ from our estimates. Such differences could be material to the financial statements.

We believe that our application of accounting policies, and the estimates inherently required therein, are reasonable. These accounting policies and estimates are periodically reevaluated, and adjustments are made when facts and circumstances dictate a change. Historically, we have found our application of accounting policies to be appropriate, and actual results have not differed materially from those determined using necessary estimates.

Management believes certain factors and trends are important in understanding our financial performance. The critical accounting policies, judgments and estimates that we believe have the most significant effect on our financial statements are:

- valuation of inventories;
- carrying value of long-lived assets;
- software development costs
- revenue recognition;
- product warranty;
- fair value measurement of financial instruments and embedded derivatives;
- stock-based compensation; and
- income taxes.

Our accounting policies are more fully described in the notes to our condensed consolidated financial statements included in this quarterly report and in our annual report on Form 10-K for the year ended December 31, 2014. There have been no significant changes in our accounting policies for the three month period ended March 31, 2015.

### ***Off Balance Sheet Arrangements***

We do not have any off-balance sheet arrangements that have, or are reasonably likely to have, an effect on our financial condition, financial statements, revenues or expenses.

### ***Business Matters***

We are engaged in the design, manufacture, marketing and sale of wearable display devices that are worn like eyeglasses and feature built-in video screens that enable the user to view video and digital content, such as movies, computer data, the Internet or video games. Our wearable display products, known commercially as Video Eyewear (also referred to as head mounted displays (or HMDs), smart glasses, wearable displays, video glasses, personal viewers, near-eye virtual displays, and near-eye displays or NEDs) contain micro video displays that offer users a portable high-quality viewing experience. Our Video Eyewear products provide virtual large high-resolution screens, fit in a user's pocket or purse and can be viewed practically anywhere, anytime. They can also be used for virtual and augmented reality applications, in which the wearer is either immersed in a computer generated world or has their real world view augmented with computer generated information or graphics. In the 4th quarter of 2013, we started commercially shipping and selling smart glasses, a new category of Video Eyewear that has much of the capabilities of a smartphone including wireless internet access but that is worn like glasses. We produce both monocular and binocular Video Eyewear devices. Video Eyewear are designed to work with mobile electronic devices, such as cell phones, laptop computers, tablets, portable media players and gaming systems.

Our Video Eyewear products feature high performance miniature display modules, low power electronics and related optical systems. We produce both monocular and binocular Video Eyewear devices that we believe are excellent solutions for many mobile computer or video viewing requirements. With respect to our Video Eyewear products, we focus on the consumer markets for gaming and mobile video while our Virtual and Augmented Reality products are also sold in the consumer, industrial, commercial, academic and medical markets. The consumer electronics and mobile phone accessory markets in which we compete has been subject to rapid technological change including the rapid adoption of tablets and most recently larger screen sizes and display resolutions along with declining prices on mobile phones, and as a result we must continue to improve our products' performance and lower our costs. We believe our intellectual property portfolio gives us a leadership position in microdisplay electronics, waveguides, ergonomics, packaging, motion tracking and optical systems.

### ***Recent Accounting Pronouncements***

FASB ASU 2015-1, Income Statement—Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items. This ASU eliminates from GAAP the concept of extraordinary items. ASU 2015-1 is effective for the annual period ending after December 15, 2015. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption.

FASB ASU 2015-03—Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. This ASU requires that debt issuance costs be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability (same treatment as debt discounts). ASU 2015-3 is effective for the annual periods beginning after December 15, 2015. Early adoption is permitted for financial statements that not have been previously issued.

There are no other recent accounting pronouncements that are expected to have a material impact on the condensed consolidated financial statements.

### *Results of Operations*

#### *Comparison of Three Months Ended March 31, 2015 and March 31, 2014*

The following table compares the Company's consolidated statements of operations data for the three months ended March 31, 2015 and 2014.

|                                      | 3 Months Ended March 31, |            |                  |                          |    |
|--------------------------------------|--------------------------|------------|------------------|--------------------------|----|
|                                      | 2015                     | 2014       | Dollar<br>Change | % Increase<br>(Decrease) |    |
| Sales of Products                    | \$695,574                | \$649,418  | \$46,156         | 7                        | %  |
| Sales of Engineering Services        | 113,581                  | 149,000    | (35,419 )        | (24                      | %) |
| Total Sales                          | 809,155                  | 798,418    | 10,737           | 1                        | %  |
| Cost of Sales — Products             | 585,390                  | 390,649    | 194,741          | 50                       | %  |
| Cost of Sales — Engineering Services | 45,432                   | 59,600     | (14,168 )        | (24                      | %) |
| Total Cost of Sales                  | 630,822                  | 450,249    | 180,573          | 40                       | %  |
| Gross Profit                         | 178,333                  | 348,169    | (169,836 )       | (49                      | %) |
| Gross Margin %                       | 22                       | % 43       | %                |                          |    |
| Operating Expenses:                  |                          |            |                  |                          |    |
| Research and Development             | 514,707                  | 397,422    | 117,285          | 30                       | %  |
| Selling and Marketing                | 357,547                  | 364,555    | (7,008 )         | (2                       | %) |
| General and Administrative           | 2,934,907                | 479,637    | 2,455,270        | 512                      | %  |
| Depreciation and Amortization        | 59,638                   | 99,705     | (40,067 )        | (26                      | %) |
| Loss from Operations                 | (3,688,466)              | (993,150 ) | (2,695,316)      | (271                     | %) |
| Other Income (Expense)               |                          |            |                  |                          |    |
| Other Taxes                          | (11,774 )                | (21,442 )  | 9,668            | (45                      | %) |
| Foreign Exchange (Gain) Loss         | 5,271                    | (3,951 )   | 9,222            | (233                     | %) |
| Loss (Gain) on Derivative Valuation  | (1,003,427)              | 2,575,262  | (3,578,689)      | (139                     | %) |



Edgar Filing: Vuzix Corp - Form 10-Q

|  |               |             |             |         |     |
|--|---------------|-------------|-------------|---------|-----|
| Amortization of Senior Term Debt Discount            | (340,960 )    | (6,326 )    | (334,634 )  | (5290 ) | (%) |
| Interest Expense                                     | (51,496 )     | (38,487 )   | (13,009 )   | (34 )   | (%) |
| Total Other Income (Expense)                         | (1,402,386)   | 2,505,056   | (3,907,442) | (156 )  | (%) |
| (Loss) Income from Before Provision for Income Taxes | (5,090,852)   | 1,511,906   | (6,602,758) | (437 )  | (%) |
| Provision for Income Taxes                           | —             | —           | —           | —       |     |
| Net (Loss) Income                                    | \$(5,090,852) | \$1,511,906 | (6,602,758) | (437 )  | (%) |

*Sales.* The increase in product sales for the three months ended March 31, 2015 over the same period in 2014 was primarily the result of a 56% increase in monocular Video Eyewear sales of the M100 Smart Glasses and M2000AR waveguide products. M100 sales to China resumed in Q1 of 2015 and represented approximately one-third of M100 product sales versus nil revenues to China for the same period in 2014. Offsetting this increase was a 15% decrease in sales of our Wrap series of video viewers and a 67% decrease in sales of Wrap AR/VR Video Eyewear products in 2015 as compared to 2014. These Wrap products were being phased out due to planned product changes to higher resolution versions and as a result we had limited quantities left for sale as compared to the 2014 period.

Sales from our engineering programs for the three months ended March 31, 2015, decreased to \$113,581 or 24% of total sales compared to \$149,000 or 19% of total sales in the same period in 2014. During the three months ended March 31, 2015 we made our final deliveries to the Navy of our first binocular waveguide systems. We have no open orders for further engineering services and are focusing on our own product and technology development activities.

*Cost of Sales and Gross Margin.* Cost of product revenues and engineering services is comprised of materials, components, labor, warranty costs, freight costs, manufacturing overhead, and the non-cash amortization of software development costs related to the production of our products and rendering engineering services,. The decreased gross margin percentage earned in the three months ended March 31, 2015 as compared to the same period in 2014 was primarily the result of amortization of software development costs of \$71,613 in the three months ending March 31, 2015, approximately \$50,000 in lower margins earned on Lenovo M100 sales in China versus average margins earned on M100 sales made elsewhere, an \$18,350 increase in manufacturing overhead as the result of increase wage costs, and component write-offs of approximately \$50,000 related to wind down of Wrap 1200 Video Eyewear production.

*Research and Development.* Our research and development expenses consist primarily of compensation costs for personnel, related stock compensation expenses, third party services, purchase of research supplies and materials, and consulting fees related to research and development costs. Software development expenses to determine technical feasibility before final development and ongoing maintenance that are not capitalized are included in research and development costs. Comparing the three months ending March 31, 2015 versus the same period in 2014 research and development costs, there was an increase in 2015 salaries of \$76,698 versus the same period in 2014 when \$62,500 of salaries related to software development costs were capitalized, a reduction of \$33,606 in consulting fees, an increase of \$21,241 in stock compensation expense, and a \$7,662 increase in travel costs.

*Selling and Marketing.* Selling and marketing costs consist of trade show costs, advertising, travel costs, sales staff compensation costs including stock compensation expense, consulting fees and sales commissions paid to full-time staff and outside consultants. These costs decreased overall for the three months ended March 31, 2015 as compared to the same period in 2014 primarily attributable to the following main factors: lower public relations and consulting fees of \$38,915, lower web design services of \$9,364, lower trade show costs of \$7,215 all offsetting an increase in salary and stock compensation costs of \$31,204.

*General and Administrative.* General and administrative costs include professional fees, investor relations (IR) costs including shares and warrants issued for IR services, salaries and related stock compensation, travel costs, office and rental costs. These costs increased for the three months ended March 31, 2015 as compared to the same period in 2014 primarily increased because of higher non-cash compensation expense related to stock awards totaling \$1,475,000, of which \$100,000 was awarded to our attorneys; increased IR activities of \$780,337, inclusive of a non-cash expense of \$526,916 for stock and warrants awarded to consultants, \$53,055 increase in professional fees; \$52,437 in increased travel costs; and \$22,792 in increased SEC filing and share listing fees. Of the total \$2,455,270 increase in 2015 over 2014, a total of approximately \$2,100,000 was non-cash share and warrant compensation expense, resulting in a net increase of approximately \$355,000 as the result of cash general and administrative expenses explained above.

*Depreciation and Amortization.* The reduction in depreciation and amortization expense is due to assets that have become fully depreciated and lower capital expenditures over the last 2 fiscal years.

*Other Income (Expense).* Other income and expenses was primarily attributable to two items. The Company recorded a loss of \$1,003,427 on the derivative liability valuation mark-to-market revaluation for 2015 versus income of \$2,575,262 in 2014, a reduction of \$3,578,689. Secondly, we incurred \$340,960 in expenses for the amortization term debt discounts in 2015 as compared to \$6,326 in 2014, a period in which prior to when the June 2014 Notes (discussed below) were issued. The provision for other taxes for 2015 was \$11,774 compared to \$21,442 for 2014. The composition of each year's other taxes provision was primarily for franchise taxes payable to the State of Delaware, our state of incorporation, which has decreased due to the reduction in authorized capital effected in June 2014.

*Provision for Income Taxes.* There were no provisions for income taxes for the three months ended March 31, 2015 or 2014.

## **Liquidity and Capital Resources**

As of March 31, 2015, we had cash and cash equivalents of \$22,884,309, an increase of \$22,799,342 from \$84,967 as of December 31, 2014.

At March 31, 2015 we had current assets of \$24,536,038 compared to current liabilities of \$1,710,095 which resulted in a positive working capital position of \$22,825,943. At December 31, 2014, we had current liabilities of \$3,386,588 compared to current assets of \$1,959,449 which resulted in a negative working capital position of \$1,427,139. Our current liabilities are comprised principally of accounts payable, accrued expenses and notes payable.

*Operating Activities.* We used \$2,747,955 of cash for operating activities for the three months ending March 31, 2015 and \$1,073,311 in the same period in 2014. Total non-cash adjustments for the three months ending March 31, 2015 were \$3,602,092 reflecting a net loss adjusted for non-cash items of \$1,488,760 as compared to a net loss adjusted for non-cash items of \$937,978 after non-cash adjustments of \$2,449,884 for the same period in 2014. The major cash operating items for the three months ending March 31, 2015 resulted from a \$1,355,578 decrease in accounts payable, a \$101,493 decrease in customer deposits and a \$101,518 increase in inventory, offset by a \$128,407 reduction in accounts receivable and a \$164,821 reduction in prepaid expenses. The major cash operating items for the three month period ending March 31, 2014 were a \$146,719 decrease in accounts payable, a \$136,026 reduction in prepaid expenses, and an \$82,047 increase in accrued in inventory.

*Investing Activities.* Cash used in investing activities was \$26,219 for the three months ending March 31, 2015 as compared to \$348,899 in the same period in 2014. During the first quarter of 2015, \$18,310 was used primarily for the purchase of computer equipment additions, as compared to spending of \$57,009 for the same period in 2014, primarily for the purchase of manufacturing equipment and mold tooling computer equipment additions. During the first quarter of 2014, a total of \$280,585 in software development costs related to our M100 product was capitalized, versus \$-0- for the same current period in 2015 when no amounts were capitalized. The costs of registering our intellectual property rights, included in the investing activities totals described above, were \$7,909 in the three month period ending March 31, 2015 and \$11,305 in the same period in 2014.

*Financing Activities.* Cash provided by financing activities was \$25,573,516 for the three months ending March 31, 2015, whereas in the same period in 2014, our net financing activities provided \$1,383,882. During the three month period ending March 31, 2015, the primary source of cash were the proceeds of \$24,813,000 from the sale of Series A Preferred Stock on January 2, 2015 to Intel Corporation (discussed below), less direct offering costs of \$221,669 and the cash proceeds of \$1,200,751 from warrant exercises. During the three month period ending March 31, 2014, the primary source of cash were proceeds of \$1,447,425 from warrant exercises less the repayments of leases and notes totaling \$63,543.

*Capital Resources.* As of March 31, 2015, we had a cash balance of \$22,884,309.

On January 2, 2015 (the "Series A Closing Date"), we entered into and closed a Series A Preferred Stock Purchase Agreement (the "Series A Purchase Agreement") with Intel Corporation (the "Series A Purchaser"), pursuant to which we issued and sold to the Series A Purchaser, an aggregate of 49,626 shares of the Company's Series A Preferred Stock, at a purchase price of \$500 per share, for an aggregate purchase price of \$24,813,000 (the "Series A Private Placement"). Each share of Series A Preferred Stock is convertible, at the option of the Series A Purchaser, into 100 shares of the Company's common stock (determined by dividing the Series A Original Issue Price of \$500 by the Series A Conversion Price. The Series A Conversion Price is \$5.00, subject to adjustment in the event of stock splits, dividends or other combinations).

Each share of Series A Preferred Stock is entitled to receive dividends at a rate of 6% per annum, compounded quarterly and payable in cash or in kind, at the Company's sole discretion. In the event of the liquidation, dissolution or winding up of the Company, each share of Series A Preferred Stock is entitled to a liquidation preference equal to one times (1x) the Series A Purchaser's original per share purchase price, plus a right to receive an additional liquidation distribution together with the common stock holders pro rata on an as converted basis, but not in excess of \$1,000 per share in the aggregate (subject to adjustment for accrued but unpaid dividends and in the event of stock splits, dividends or other combinations). Each share of Series A Preferred Stock is entitled to vote with the holders of the Company's common stock on matters presented to its stockholders, and is entitled to cast such number of votes equal to the whole number of shares of common stock into which such shares of Series A Preferred Stock are convertible. The holders of record of the Series A Preferred Stock will be entitled to nominate and elect 2 directors to the Company's Board of Directors (the "Board Election Right"), at least one of whom will be required to qualify as an "independent" director, as that term is used in applicable exchange listing rules. The Board Election Right with respect to the independent director will terminate on such date as the number of shares of Series A Preferred Stock then outstanding is less than 40% of the original amount purchased by the Series A Purchaser. The Board Election Right with respect to the second director shall terminate on such date as the number of shares of Series A Preferred Stock then outstanding is less than 20% of the original amount purchased by the Series A Purchaser. The Company also granted the Series A Purchaser the right to have a board observer at meetings of the Company's Board of Directors and committees thereof. As of the date of the filing of this Quarterly Report, the Series A Purchaser has not requested the appointment of its 2 directors nor asked to have its observer attend board meetings.

For as long as at least 25% (or 12,406 shares) of the Series A Preferred Stock is outstanding, the Company may not, without the consent of holders of at least 60% of the then outstanding shares of Series A Preferred Stock, take certain actions, including but not limited to: (i) liquidate, dissolve, or wind up the business and affairs of the Company; (ii) amend, alter or repeal any provision of its charter or bylaws in a manner that adversely effects the rights of the Series A Preferred Stock; (iii) create or issue any capital stock that is equal to or senior to the Series A Preferred Stock with respect to preferences; (iv) create or issue any debt security, subject to certain exceptions; (v) pay off any debt obligation prior to its stated maturity date; or (vi) enter into any stockholders rights plan or similar arrangement or take other actions that may limit actions that holders of a majority of the Series A Preferred Stock can take under Section 203 ("Section 203") of the Delaware General Corporation Law, as well as such other customary provisions protecting the rights of the holder of the Series A Preferred Stock, as are outlined in the Certificate of Designation.

The Series A Purchaser has the right to participate in any proposed issuance by the Company of its securities, subject to certain exceptions (the “Participation Right”). In the event the Series A Purchaser is not afforded the opportunity to exercise its Participation Right, the Series A Purchaser will have the right, but not the obligation, up to two times per calendar year, to acquire additional securities from the Company in such amount as is sufficient to maintain the Series A Purchaser’s ownership percentage in the Company, calculated immediately prior to such applicable financing, at a purchase price equal to the per share price of the Company’s securities in such applicable financing.

Additionally, the Company’s Board of Directors approved the Offering for purposes of Section 203, which prohibits transactions with interested stockholders under Delaware state law. The Board of Directors approved the exemption of the Series A Purchaser from Section 203 with respect to any future business combinations or other transactions covered by Section 203 and, for such purposes, the Series A Purchaser will not be deemed an “interested stockholder”. Furthermore, the Board of Directors has waived any claims based on the corporate opportunity doctrine under Delaware state law or with respect to any duty of the Series A Purchaser, the directors appointed pursuant to the Board Election Right or the board observer, to disclose any information regarding the Series A Purchaser that may be of interest to the Company or permit the Company to participate in any projects or investments based on such information.

In connection with the Series A Private Placement, the Company entered into an investor’s rights agreement with the Series A Purchaser, pursuant to which the Company agreed to file a “resale” registration statement with the Securities and Exchange Commission (the “SEC”) covering all shares of common stock issuable upon conversion of the Series A Preferred Stock sold in the Series A Private Placement. The Company filed the registration statement on February 12, 2015 and the registration statement was declared effective by SEC on February 17, 2015.

In connection with the Series A Private Placement, each of the holders of notes issued by the Company on June 3, 2014 (the “June 2014 Notes”) agreed to irrevocably waive their rights to anti-dilution protection under Section 5(b) of the June 2014 Notes in the event the Company issues additional securities at a per share price lower than the conversion price of the June 2014 Notes (the “June 2014 Note Waiver”). The obligations of the holder of the June 2014 Notes under the June 2014 Note Waiver will be binding on all assignees of the June 2014 Notes. Additionally, holders of the June 2014 Notes waived their rights of participation with respect to the June 2014 Private Placement and agreed to subordinate their participation rights to the Series A Purchaser’s Participation Right.

In connection with the Series A Private Placement, holders of approximately 86% of outstanding warrants issued by the Company in its public offering on August 5, 2013 and in connection with the conversion by certain holders of the Company’s outstanding debt in connection with the Company’s public offering (collectively, the “Public Offering Warrants”) agreed to irrevocably waive their rights to anti-dilution protection under Section 2(b) of the Public Offering Warrants in the event the Company issues additional securities at a per share price lower than the exercise price of the Public Offering Warrants (the “Public Offering Warrant Waiver”). The obligations of the holder of the Public Offering Warrants under the Public Offering Warrant Waiver will be binding on all assignees of the July 2013 Warrants.

During the first quarter of 2015, the Company received exercise notices with respect to an aggregate of 4,665,892 warrants issued pursuant to the Company's public offering at an exercise price of \$2.25 per share. A total of 504,500 of these warrants were exercised for cash along with 26,250 underwriter cash warrant exercises related to that same offering, netting total proceeds of \$1,200,751 to the Company. A further 4,161,392 of these public offering warrants and 6,875 underwriter warrants were exercised on a cashless basis resulting in the issuance of 3,549,624 and 4,380 common shares, respectively. There are currently 57,600 investor and 70,125 underwriter warrants outstanding from the August 2013 public offering.

Additionally, \$337,500 in convertible notes were converted to common stock during the first quarter of 2015. Total convertible notes outstanding as of the date of March 31, 2015, excluding accrued interest is \$2,037,500, which is convertible into 905,556 shares.

We will need to continue to increase our product sales to achieve positive cash flow from operations. We have developed an operating plan which includes the expansion of our existing premises and personnel resources. As part of this plan we will be relocating our corporate offices, research and development facilities and manufacturing to a facility approximately 4 times our existing facility by early fall 2015. This relocation will include the installation of new cleanroom space to meet the expanded production needs of our waveguide optics. Most of the new personnel resources will be focused on research and development staff and select marketing and sales personnel as well as some finance head count increases to improve the Company's financial reporting controls. We intend to introduce several new products over the next year including our award winning IWear 720 (formerly named the V720) Video Headphones, successor models of the M100 Smart Glasses and new Smart Glass products based on our waveguide optics technologies. Such expenditures, along with further future net operating losses, product tooling expenses, and related working capital investments, will be the principal use of our cash.

We believe our existing cash and cash equivalent balances and cash flow from future operations will be sufficient to meet our working capital and capital expenditure needs for the foreseeable future even with continued operating losses similar in size to the amounts reported for the three months ending March 31, 2015 and for the year ended December 31, 2014. There can however be no assurance that we will be able to generate positive cash flows from operations in the future.

### **Forward Looking Statements**

This quarterly report includes forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our management's beliefs and assumptions and on information currently available to our management. Forward-looking statements include statements concerning:

- Our cash needs and financing plans;
- Our possible or assumed future results of operations;
- Our business strategies;
- Our ability to attract and retain customers;
- Our ability to sell additional products and services to customers;
- Our competitive position;
- Our industry environment;
- Our potential growth opportunities;
- Expected technological advances by us or by third parties and our ability to leverage them;
- The effects of future regulation; and
- The effects of competition.

All statements in this quarterly report that are not historical facts are forward-looking statements. We may, in some cases, use terms such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "projects," "should," "will," "would" or similar expressions that convey uncertainty of future events or outcomes to identify forward-looking statements.



The outcome of the events described in these forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These important factors include our financial performance and the other important factors set forth in our annual report on Form 10-K for the year ended December 31, 2014 and in other filings with the Securities and Exchange Commission.

All such forward-looking statements are subject to certain risks and uncertainties and should be evaluated in light of important risk factors. These risk factors include, but are not limited to, those that are described in "Risk Factors" under Item 1A and elsewhere in our 2014 annual report on Form 10-K and the following: business and economic conditions, rapid technological changes accompanied by frequent new product introductions, competitive pressures, dependence on key customers, inability to gauge order flows from customers, fluctuations in quarterly and annual results, the reliance on a limited number of third party suppliers, limitations of our manufacturing capacity and arrangements, the protection of our proprietary technology, the effects of pending or threatened litigation, the dependence on key personnel, changes in critical accounting estimates, potential impairments related to investments, foreign regulations, liquidity issues, and potential material weaknesses in internal control over financial reporting. Further, during weak or uncertain economic periods, customers' may delay the placement of their orders. These factors often result in a substantial portion of our revenue being derived from orders placed within a quarter and shipped in the final month of the same quarter.

Any of these factors could cause our actual results to differ materially from our anticipated results. For a more detailed discussion of these factors, see the "Risk Factors" discussion in Item 1A in our 2014 annual report. We caution readers to carefully consider such factors. Many of these factors are beyond our control. In addition, any forward-looking statements represent our estimates only as of the date they are made, and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, except as may be required under applicable securities laws, we specifically disclaim any obligation to do so, even if our estimates change.

### **Item 3. Quantitative and Qualitative Disclosures about Market Risk**

Not required for a smaller reporting company.

### **Item 4. Controls and Procedures**

#### Disclosure Controls and Procedures

We maintain a system of disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in reports that we file or submit under the Securities Exchange Act of 1934, as amended (the "Exchange Act") is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's (SEC) rules and forms. Disclosure controls are also designed to reasonably assure that such information is accumulated and communicated to management, including the Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), as appropriate to allow timely decisions regarding required disclosure. Disclosure controls include components of internal control over financial reporting, which consists of control processes designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP.

As reported in our 2014 Annual Report on Form 10-K (the "2014 Form 10-K"), as of December 31, 2014, our management identified material weaknesses in our internal control over financial reporting that have a direct impact on our financial reporting. Due to these material weaknesses in internal control over financial reporting, our management concluded in our 2014 Form 10-K that our disclosure controls and procedures were ineffective as of December 31, 2014.

Our management, with the participation of our CEO and CFO, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2015. As part of its evaluation, our management has evaluated whether the control deficiencies related to the reported material weakness in internal control over financial reporting continue to exist. As of March 31, 2015, we have not completed the development, assessment, implementation and testing of the changes in controls and procedures that we believe are necessary to conclude that the material weakness has been remediated and, therefore, our management has concluded that we cannot assert that the control deficiencies relating to the reported material weakness have been effectively remediated. As a result, our CEO and CFO have concluded that our disclosure controls and procedures were ineffective as of March 31, 2015.

In light of the foregoing conclusion, we undertook additional procedures in order that management could conclude that reasonable assurance exists regarding the reliability of financial reporting and the preparation of the consolidated

financial statements contained in this filing. Accordingly, management believes that our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for the period ended March 31, 2015 fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented.

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis. In its assessment of the effectiveness of internal control over financial reports as of December 31, 2014, we determined that there were control deficiencies that constituted the following material weaknesses that continue to exist as of March 31, 2015:

### **Deficiencies in Financial Reporting and Close Process**

Our current financial close process does not ensure accurate financial reporting on a timely basis. We also did not maintain effective controls over the period-end financial close and reporting processes in relation to the consolidation of our subsidiary's financial information. The specific deficiencies contributing to this material weakness related (a) to inadequate policies and procedures, (b) ineffective procedures and controls over journal entries, accruals and reserves, (c) inadequate controls and procedures related to the timely preparation and review of account reconciliations, (d) inadequate segregation of duties, (e) inadequate controls over cut-off procedures, (f) deficiencies in end-user computing controls of critical spreadsheets, and (g) an insufficient complement of personnel with appropriate levels of knowledge and experience. Due to the actual and potential errors on financial statement balances and disclosures, management has concluded that these deficiencies in internal controls over the period-end financial close and reporting processes constituted a material weakness in internal control over financial reporting. We intend to establish and document financial close processes and procedures including responsibilities and due dates. We also intend to commence utilizing a closing checklist to ensure all procedures are performed and appropriate reviews are completed on a timely basis for each quarter and year-end period. Additionally, we intend to implement controls over critical spreadsheets, including change control, input control, access and data security and appropriate review procedures. Further, we intend to seek additional resources with strong accounting and reporting experience when financial resources are available. We cannot give any assurance as to whether or when we will be able to implement those changes.

### **Deficiencies in Segregation of Duties**

There is limited segregation of duties which could result in a material misstatement in our financial statements. Given our staff levels, certain duties within the accounting and finance department cannot be properly segregated. However, we believe that none of these segregation of duty deficiencies resulted in material misstatement in the financial statements as we rely on certain compensating controls, including periodic substantive review of the financial statements by the Chief Executive Officer and Chief Financial Officer.

### **Deficiencies in Monitoring of Subsidiaries**

We have not designed adequate monitoring controls related to our European subsidiary or Japanese branch sales office, such that we can be assured that a material misstatement of financial results would be prevented or detected on a timely basis.

### **Weaknesses in Inventory Controls**

We have identified weaknesses in our inventory controls as follows:

Documented processes and controls are insufficient and are not working effectively for several key inventory processes including inventory adjustments and reserves for excess, defective and obsolete inventory.

Inventory valuation processes and controls are not sufficiently documented and are not working effectively including costs to be expensed versus inventoried and maintenance of adequate supporting documentation for current unit costs and bill of materials.

### **Deficiencies in Internal Controls Procedures and Risk Assessment Program**

We have concluded that formal written internal control policies and procedures do not currently exist for all areas within our operations. A well-established and documented internal control structure is pertinent to our ability to maintain accurate books and records, prevent and detect fraud, maintain segregation of duties, report timely financial results and to properly comply with management's requirements to report on the effectiveness of internal controls over financial reporting pursuant to the Sarbanes-Oxley Act. In determining key controls and appropriate internal controls for us management needs to further develop its risk assessment process, including a fraud risk assessment and monitoring program, that is appropriate for our size and complexity, to assess the risks of material misstatement in the

significant accounts and disclosures and related assertions and to ensure implementation of controls to prevent or detect errors or fraud that could result in material misstatements.

### **Changes in internal control over financial reporting**

During the three months ended March 31, 2015, there were no changes in our internal controls that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## **Part II. OTHER INFORMATION**

### **Item 1. Legal Proceedings**

We are not currently involved in any pending legal proceeding or litigation and we are not aware of any such proceedings contemplated by or against us or our property. To our knowledge, there are no material legal proceedings to which any our directors, officers or affiliates, or any beneficial owner of more than five percent of our common stock, or any associate of any of the foregoing, is a party adverse to us or any of our subsidiaries or has a material interest adverse to us or any of our subsidiaries.

### **Item 1A. Risk Factors**

In addition to the other information set forth in this report you should carefully consider the factors discussed in Part I, Item 1A. "Risk Factors" in our annual report on Form 10-K for the year ended December 31, 2014. There have been no material changes from those risk factors. The risks discussed in our 2014 annual report could materially affect our business, financial condition and future results.

### **Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

Sale of Unregistered Securities –

During the three months ended March 31, 2015 we issued 40,000 shares of common stock and 60,000 warrants for investor relations services.

During the three months ended March 31, 2015 we issued 30,630 shares upon the exercise of warrants issued to the underwriter in connection with our August 5, 2013 public offering.

During the three months ended March 31, 2015 we issued a total of 275,000 shares to two officers and three directors of the Company and 20,000 shares to the Company's law firm for services provided.

During the three months ended March 31, 2015, we issued 150,000 shares of common stock upon conversion of convertible notes in the principal amount of \$337,500.

In connection with the foregoing, we relied upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended, for transactions not involving a public offering.

Purchase of Equity Securities - none

**Item 3. Defaults Upon Senior Securities**

None

**Item 4. Mine Safety Disclosures**

Not Applicable

**Item 5. Other Information**

None

**Item 6. Exhibits**

**Exhibit No. Description**

- 31.1 Certification of the Chief Executive Officer of the Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2 Certification of the Chief Financial Officer of the Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32.1 Certification of the Chief Executive Officer of the Registrant pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 32.2 Certification of the Chief Financial Officer of the Registrant pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS XBRL Instance Document

101.SCH XBRL Taxonomy Extension Schema Document

101.CAL XBRL Taxonomy Extension Calculation Link base Document

101.DEF XBRL Taxonomy Extension Definition Link base

101.LAB XBRL Taxonomy Extension Label Link base Document

101.PRE XBRL Taxonomy Extension Presentation Link base Document

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**VUZIX CORPORATION**

Date: May 12, 2015 By: /s/ Paul J. Travers  
Paul J. Travers  
President, Chief Executive Officer  
(Principal Executive Officer)

Date: May 12, 2015 By: /s/ Grant Russell  
Grant Russell  
Executive Vice President and Chief Financial Officer  
(Principal Financial and Accounting Officer)